Viridian Therapeutics, Inc. (VRDN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Stephen F. Mahoney J.D., MBA
|
CEO, President & Director | 1.34M | -- | 1971 |
|
Mr. Seth Harmon
|
Chief Financial Officer | 785.65k | -- | 1981 |
|
Mr. Thomas W. Beetham J.D., MBA
|
Chief Operating Officer | 972.98k | -- | 1970 |
|
Ms. Jennifer Tousignant J.D.
|
Chief Legal Officer & Corporate Secretary | 819.95k | -- | 1973 |
|
Dr. Radhika Tripuraneni M.D., M.P.H.
|
Chief Medical Officer | 840.69k | -- | 1980 |
|
Dr. Eric N. Olson Ph.D.
|
Co-Founder & Chairman of Scientific Advisory Board | -- | -- | -- |
|
Dr. Michael R. Bristow M.D., Ph.D.
|
Co-Founder & Member of the Scientific Advisory Board | -- | -- | 1945 |
|
Dr. Marvin H. Caruthers Ph.D.
|
Co-Founder & Scientific Advisory Board Member | -- | -- | 1940 |
|
Mr. Vahe Bedian Ph.D.
|
Co-Founder & Scientific Advisor | -- | -- | -- |
|
Ms. Melissa Manno
|
Chief Human Resources Officer | -- | -- | -- |
Viridian Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 252
Description
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
November 4, 2026 at 1:30 PM UTC
Viridian Therapeutics, Inc. Earnings Date
